- Home
- QTRX
as 11-07-2024 4:00pm EST
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory, Homebrew - Custom Assay Development, and Uman NF-Light.
Upcoming Earnings Alert:
Get ready for potential market movements as Quanterix Corporation QTRX prepares to release earnings report on 12 Nov 2024.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | BILLERICA |
| Market Cap: | 492.0M | IPO Year: | 2017 |
| Target Price: | $23.00 | AVG Volume (30 days): | 372.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.50 - $29.70 | Next Earning Date: | 11-12-2024 |
| Revenue: | $129,330,000 | Revenue Growth: | 15.52% |
| Revenue Growth (this year): | 13.56% | Revenue Growth (next year): | 16.61% |
Stock Insider Trading Activity of Quanterix Corporation (QTRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WALT DAVID R | QTRX | Director | Aug 20 '24 | Buy | $13.29 | 47,000 | $624,630.00 | 1,487,342 | |
| Toloue Masoud | QTRX | President & CEO | Aug 13 '24 | Buy | $10.90 | 19,000 | $207,100.00 | 354,119 |
Latest Quanterix Corporation News
QTRX Breaking Stock News: Dive into QTRX Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024
Business Wire
10 days ago
New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer’s Disease Diagnostic Information
GuruFocus.com
a month ago
Quanterix Corp (QTRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amid Regional ...
Business Wire
a month ago
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors
Zacks
a month ago
Brainsway (BWAY) Soars 14.5%: Is Further Upside Left in the Stock?
MT Newswires
a month ago
Quanterix Starts Selling Alzheimer's Disease Testing Kit for Research Use
Business Wire
a month ago
Quanterix Announces Commercialization of p-Tau 217 Test Kit
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 09/18/2024
Compare QTRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QTRX Quanterix Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.